Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase …
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the first results from …
Analysts are weighing in on biotech companies bluebird bio Inc (NASDAQ:BLUE) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO), with mixed ratings.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its clinical development strategy for the company’s lead cancer metabolism and rare genetic metabolic disorders programs, along with insights …
Canaccord’s healthcare analyst John Newman weighed in with a few insights on Agios Pharmaceuticals Inc (NASDAQ:AGIO), as the company’s AG-120 solid tumor data will be presented …
Recently, various executives have taken part in insider selling activity for the stocks of Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Kite Pharma Inc (NASDAQ:KITE), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Pacira …
Canaccord Genuity analyst John Newman came out today with some cautious stance on Agios Pharmaceuticals Inc (NASDAQ:AGIO), as the company will present data for AG-120 in …
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results …
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced that the company’s board …
Canaccord Genuity analyst John Newman came out today with a research report on Agios Pharmaceuticals Inc (NASDAQ:AGIO), reducing the price target to $93 (from $103), …
